The FDA continues to recommend that Hospira’s potassium phosphates not be used in parenteral nutrition for pediatric patients. The Food and Drug Administration (FDA) has issued an updated warning ...
The FDA warned healthcare workers and pharmacies on Feb. 9 not to use an unapproved potassium phosphates drug made by Hospira, a Pfizer company, in pediatric patients because the aluminum exposure can ...
Healthcare workers and pharmacies should stop using unapproved potassium phosphates drug products from Hospira in pediatric patients due to unsafe levels of aluminum, the FDA warned on Thursday.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has received New Drug Application (“NDA”) approval from the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback